| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Basic Science Investigation |
1 Department of Biomedical Physics, School of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom; and 2 Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom
Correspondence: For correspondence or reprints contact: Tim A.D. Smith, PhD, Department of Biomedical Physics, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD U.K. E-mail: t.smith{at}biomed.abdn.ac.uk
Mutations in the p53 gene, often resulting in loss of wild-type (WT) p53 expression, are found at high frequencies in several cancer types. High uptake of 18F-FDG detected using 18F-FDG PET has been associated with a poor prognosis. To determine whether high 18F-FDG uptake may be related to decreased expression of WT p53, we examined 18F-FDG uptake in cells transfected with dominant negative p53 constructs that abrogate WT p53 function. Methods: Two clones of MCF-7 breast cancer cells were stably transfected with a dominant negative p53 construct. 18F-FDG uptake, hexokinase (HK) activity, and glucose transport were measured in each clone and in the control WT cells from which the clones had been derived. The expression of glucose transporters, HKs, and glucose-6-phosphatase was determined using microarray technology. Results: Microarray experiments revealed that glucose transporters 1, 8, and 10 were expressed in MCF-7 cells, whereas glucose-6-phosphatase was absent. HK I was the principal HK in MCF-7 cells but was not differentially expressed at the messenger RNA level in the dominant negative p53 clones, compared with WT cells. However, increased HK activity was observed in both dominant negative p53 clones, compared with WT MCF-7. 18F-FDG uptake was increased in both clones expressing the dominant negative p53 constructs. Conclusion: These data suggest that abrogation of p53 in breast cancer is associated with specific changes in glucose metabolism detected by PET.
Key Words: GLUT • 18F-FDG • cancer • hexokinase • p53
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  H. Jadvar, A. Alavi, and S. S. Gambhir 18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization J. Nucl. Med., November 1, 2009; 50(11): 1820 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Sharma and T. A.D. Smith Colorectal Tumor Cells Treated with 5-FU, Oxaliplatin, Irinotecan, and Cetuximab Exhibit Changes in 18F-FDG Incorporation Corresponding to Hexokinase Activity and Glucose Transport J. Nucl. Med., August 1, 2008; 49(8): 1386 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ueda, H. Tsuda, H. Asakawa, T. Shigekawa, K. Fukatsu, N. Kondo, M. Yamamoto, Y. Hama, K. Tamura, J. Ishida, et al. Clinicopathological and Prognostic Relevance of Uptake Level using 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) in Primary Breast Cancer Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 250 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A.D. Smith and M. G. Blaylock Treatment of Breast Tumor Cells In Vitro with the Mitochondrial Membrane Potential Dissipater Valinomycin Increases 18F-FDG Incorporation J. Nucl. Med., August 1, 2007; 48(8): 1308 - 1312. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
